Federal Circuit Invalidates Merck’s Cladribine Patents in TWi Pharma Victory
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Merck KGaA v. TWi Pharmaceuticals, Inc. |
| Case Number | 1:24-cv-00700 (D. Del.) |
| Court | Federal Circuit, Appeal from D. Del. |
| Duration | June 2024 – Feb 2026 1 year 7 months |
| Outcome | Defendant Win — Patents Invalidated |
| Patents at Issue | |
| Accused Products | TWi’s Cladribine 10 mg Tablets |
Case Overview
The Parties
⚖️ Plaintiff
A multinational science and technology company with a robust pharmaceutical portfolio, holding patents for cladribine, marketed as Mavenclad®.
🛡️ Defendant
A generic drug developer focused on complex formulation challenges and a successful challenger of branded pharmaceutical patents.
The Patents at Issue
This landmark case involved two patents covering cladribine tablet formulations, crucial for Merck’s Mavenclad® product used in multiple sclerosis treatment. These patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • US 7,713,947 — Cladribine formulation technology
- • US 8,377,903 — Related formulation methods and compositions
Developing a new drug formulation?
Check if your pharmaceutical formulation might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Delaware District Court entered final judgment **entirely in favor of TWi Pharmaceuticals**: Claims 36, 38, 39, and 41–46 of the **’947 patent** were adjudged **invalid as obvious**, and Claims 17, 19, 20, and 22–27 of the **’903 patent** were adjudged **invalid as obvious**. All of Merck’s infringement claims were dismissed. This outcome highlights the aggressive scrutiny courts apply to formulation patents under **35 U.S.C. § 103 obviousness**.
Key Legal Issues
The Federal Circuit’s ruling, with a mandate entered January 29, 2026, focused squarely on the **obviousness** of the cladribine formulations. Pharmaceutical formulation patents are particularly vulnerable to obviousness attacks, as formulation science often builds incrementally on established principles. The Federal Circuit’s swift resolution indicates the obviousness case was sufficiently clear-cut, setting a strong precedent for future challenges to similar formulation patents.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulation. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related pharmaceutical patents in this technology space
- See which companies are most active in drug formulation patents
- Understand claim construction patterns for pharmaceutical formulations
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug formulation or technology.
- Input your drug formulation description or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report for pharma products
High Risk Area
Formulation patents for known APIs
2 Patents Invalidated
Cladribine formulation patents
Obviousness Defense
Proven successful for generic entry
✅ Key Takeaways
Federal Circuit invalidated cladribine formulation claims (U.S. Patent Nos. 7,713,947 and 8,377,903) as obvious in Case No. 1:24-cv-00700.
Search related case law →Consolidated appellate strategy (Nos. 2025-1463/2025-1464) efficiently resolved multi-patent disputes before full trial.
Explore precedents →Obviousness remains the dominant validity challenge for pharmaceutical formulation patents.
Attorneys’ fees exposure under 35 U.S.C. § 285 remains open pending appeal deadlines.
Frequently Asked Questions
U.S. Patent Nos. 7,713,947 and 8,377,903, covering cladribine tablet formulations.
The Federal Circuit found the asserted patent claims invalid as obvious under 35 U.S.C. § 103, with the Delaware District Court entering final judgment implementing that ruling on February 2, 2026.
It reinforces that formulation patents built on known APIs face significant obviousness risk, particularly where prior art discloses the active ingredient and standard formulation approaches.
Ready to Strengthen Your Pharma Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in the pharmaceutical sector.
References
- United States Court of Appeals for the Federal Circuit — Case Nos. 2025-1463 and 2025-1464
- U.S. District Court for the District of Delaware — Case 1:24-cv-00700
- U.S. Patent and Trademark Office — Patent Center
- Cornell Legal Information Institute — 35 U.S.C. § 103
- Cornell Legal Information Institute — 35 U.S.C. § 285
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.